0001213900-22-006107.txt : 20220209 0001213900-22-006107.hdr.sgml : 20220209 20220209140101 ACCESSION NUMBER: 0001213900-22-006107 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20220209 DATE AS OF CHANGE: 20220209 EFFECTIVENESS DATE: 20220209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Precise Bio, Inc. CENTRAL INDEX KEY: 0001904090 IRS NUMBER: 474571992 STATE OF INCORPORATION: DE FISCAL YEAR END: 1221 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-432895 FILM NUMBER: 22605746 BUSINESS ADDRESS: STREET 1: 111 NORTH CHESTNUT STREET, SUITE 103 CITY: WINSTON-SALEM STATE: NC ZIP: 27101-4054 BUSINESS PHONE: 336.955.1120 MAIL ADDRESS: STREET 1: 111 NORTH CHESTNUT STREET, SUITE 103 CITY: WINSTON-SALEM STATE: NC ZIP: 27101-4054 D 1 primary_doc.xml X0708 D LIVE 0001904090 Precise Bio, Inc. 111 NORTH CHESTNUT STREET, SUITE 103 WINSTON-SALEM NC NORTH CAROLINA 27101-4054 336.955.1120 DELAWARE None None Corporation true Aryeh Batt 1 Ha-Ganan Street Modi'in Macabim Reut L3 ISRAEL 7169524 Executive Officer Director Promoter Avi Katz 111 North Chestnut Street, Suite 103 Winston-Salem NC NORTH CAROLINA 27101-4054 Executive Officer Director Anthony Atala 111 North Chestnut Street, Suite 103 Winston-Salem NC NORTH CAROLINA 27101-4054 Director Promoter Shay Soker 111 North Chestnut Street, Suite 103 Winston-Salem NC NORTH CAROLINA 27101-4054 Director Promoter Ilan Lior 1 Ha-Ganan Street Modi'in Macabim Reut L3 ISRAEL 7169524 Director Yalon Farhi 1 Ha-Ganan Street Modi'in Macabim Reut L3 ISRAEL 7169524 Director Biotechnology Decline to Disclose 06b false 2018-11-03 true true true SAFE (Simple Agreement for Future Equity) false 15000 Nobel Capital 15768 None None 150 EAST PALMETTO PARK ROAD; SUITE 110 BOCA RATON, FL FLORIDA 33432 AL ALABAMA CA CALIFORNIA CO COLORADO CT CONNECTICUT FL FLORIDA IL ILLINOIS MA MASSACHUSETTS MN MINNESOTA NV NEVADA NY NEW YORK OH OHIO OR OREGON TX TEXAS WI WISCONSIN true 15530000 15530000 0 false 70 730000 true 557000 true Commissions also include warrants and equity based commissions. 700000 true The gross proceeds are being used to fund development and other operating expenses. The payments described in this Item 16 include salary payments to the executive officers named in Item 3, above. false Precise Bio, Inc. /s/ EYAL ARIELI EYAL ARIELI CFO 2021-12-08